RT Journal Article
SR Electronic
T1 Genetic modifiers and ascertainment drive variable expressivity of complex disorders
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.27.24312158
DO 10.1101/2024.08.27.24312158
A1 Jensen, Matthew
A1 Smolen, Corrine
A1 Tyryshkina, Anastasia
A1 Pizzo, Lucilla
A1 Banerjee, Deepro
A1 Oetjens, Matthew
A1 Shimelis, Hermela
A1 Taylor, Cora M.
A1 Pounraja, Vijay Kumar
A1 Song, Hyebin
A1 Rohan, Laura
A1 Huber, Emily
A1 El Khattabi, Laila
A1 van de Laar, Ingrid
A1 Tadros, Rafik
A1 Bezzina, Connie
A1 van Slegtenhorst, Marjon
A1 Kammeraad, Janneke
A1 Prontera, Paolo
A1 Caberg, Jean-Hubert
A1 Fraser, Harry
A1 Banka, Siddhartha
A1 Van Dijck, Anke
A1 Schwartz, Charles
A1 Voorhoeve, Els
A1 Callier, Patrick
A1 Mosca-Boidron, Anne-Laure
A1 Marle, Nathalie
A1 Lefebvre, Mathilde
A1 Pope, Kate
A1 Snell, Penny
A1 Boys, Amber
A1 Lockhart, Paul J.
A1 Ashfaq, Myla
A1 McCready, Elizabeth
A1 Nowacyzk, Margaret
A1 Castiglia, Lucia
A1 Galesi, Ornella
A1 Avola, Emanuela
A1 Mattina, Teresa
A1 Fichera, Marco
A1 Bruccheri, Maria Grazia
A1 Mandarà, Giuseppa Maria Luana
A1 Mari, Francesca
A1 Privitera, Flavia
A1 Longo, Ilaria
A1 Curró, Aurora
A1 Renieri, Alessandra
A1 Keren, Boris
A1 Charles, Perrine
A1 Cuinat, Silvestre
A1 Nizon, Mathilde
A1 Pichon, Olivier
A1 Bénéteau, Claire
A1 Stoeva, Radka
A1 Martin-Coignard, Dominique
A1 Blesson, Sophia
A1 Le Caignec, Cedric
A1 Mercier, Sandra
A1 Vincent, Marie
A1 Martin, Christa
A1 Mannik, Katrin
A1 Reymond, Alexandre
A1 Faivre, Laurence
A1 Sistermans, Erik
A1 Kooy, R. Frank
A1 Amor, David J.
A1 Romano, Corrado
A1 Andrieux, Joris
A1 Girirajan, Santhosh
YR 2024
UL http://medrxiv.org/content/early/2024/08/28/2024.08.27.24312158.abstract
AB Variable expressivity of disease-associated variants implies a role for secondary variants that modify clinical features. We assessed the effects of modifier variants towards clinical outcomes of 2,252 individuals with primary variants. Among 132 families with the 16p12.1 deletion, distinct rare and common variant classes conferred risk for specific developmental features, including short tandem repeats for neurological defects and SNVs for microcephaly, while additional disease-associated variants conferred multiple genetic diagnoses. Within disease and population cohorts of 773 individuals with the 16p12.1 deletion, we found opposing effects of secondary variants towards clinical features across ascertainments. Additional analysis of 1,479 probands with other primary variants, such as 16p11.2 deletion and CHD8 variants, and 1,084 without primary variants, showed that phenotypic associations differed by primary variant context and were influenced by synergistic interactions between primary and secondary variants. Our study provides a paradigm to dissect the genomic architecture of complex disorders towards personalized treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIH R01-GM121907 and resources from the Huck Institutes of the Life Sciences to S.G. M.J. and C.S. were supported by NIH T32-GM102057. A.T. was supported by NIH T32-LM012415. L.P. was supported by Fulbright Commission Uruguay-ANII. A.R. was supported by grants from the Swiss National Science Foundation 31003A_182632. S.B. was supported by the NIHR Manchester Biomedical Research Centre (NIHR203308).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of Pennsylvania State University and Geisinger Health Systems gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWhole genome sequencing and SNP microarray data generated in this study are available at NCBI dbGaP phs002450.v2.p1. Statistical analyses and experimental results for the data presented in Figs. 2-7 and associated supplementary figures are available in Tables S2-S6.  https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002450.v2.p1 https://github.com/girirajanlab/16p12_WGS_project